ReviewJournal of the American Society of Nephrology : JASN2012
Treatment of idiopathic membranous nephropathy.
Review in Journal of the American Society of Nephrology : JASN, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 5 syntheses or guidelines pooled it.
- Efficacy and safety of cyclosporine A in the treatment of idiopathic membranous nephropathy in an Asian population.Drug design, development and therapy · 2019Pooled it
- The Influence and Role of Microbial Factors in Autoimmune Kidney Diseases: A Systematic Review.Journal of immunology research · 2015Pooled it
- Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome.The Cochrane database of systematic reviews · 2014Pooled it
- Phospholipase A2 receptor autoantibodies and clinical outcome in patients with primary membranous nephropathy.Journal of the American Society of Nephrology : JASN · 2014Pooled it
- Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials.Clinical journal of the American Society of Nephrology : CJASN · 2013Pooled it
- Narrative review on decoding the crosstalk between lipid homeostasis and immune pathways in membranous nephropathy.BMC nephrology · 2025Review
- The successful use of rituximab in IgA nephropathy patients with podocytopathy: a case series.Clinical kidney journal · 2024Article
- Primary membranous nephropathy in the Italian region of Emilia Romagna: results of a multicenter study with extended follow-up.Journal of nephrology · 2024Article
- Characteristics of hospitalized elderly patients with CKD: a comparison between elderly and non-elderly CKD based on a multicenter cross-sectional study.International urology and nephrology · 2024Article
- From KDIGO 2012 towards KDIGO 2021 in idiopathic membranous nephropathy guidelines: what has changed over the last 10 years?Journal of nephrology · 2023Review
- Rapid diagnosis of membranous nephropathy based on serum and urine Raman spectroscopy combined with deep learning methods.Scientific reports · 2023Article
- Evaluating Efficacy and Safety of Tacrolimus Treatment in Membranous Nephropathy: Results of a Retrospective Study of 182 Patients.Therapeutics and clinical risk management · 2023Article
- Yi Shen An, a Chinese traditional prescription, ameliorates membranous glomerulonephritis induced by cationic bovine serum albumin in rats.Pharmaceutical biology · 2022Article
- Mechanism of action ofRenal failure · 2022Article
- Translational research in nephrology: prognosis.Clinical kidney journal · 2022Article
- Etiology of Kidney Diseases With Proteinuria in the Gambia/West Africa.Frontiers in pediatrics · 2022Article
- Review
- Effects of CYP3A5 Polymorphisms on Efficacy and Safety of Tacrolimus Therapy in Patients with Idiopathic Membranous Nephropathy.Pharmacogenomics and personalized medicine · 2020Article
- Article
- Acute Kidney Injury Following Exposure to Calcineurin Inhibitors in a Patient with Idiopathic Membranous Nephropathy.Drug safety - case reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Exciting progress recently has been made in our understanding of idiopathic membranous nephropathy, as well as treatment of this disease. Here, we review important advances regarding the pathogenesis of membranous nephropathy. We will also review the current approach to treatment and its limitations and will highlight new therapies that are currently being explored for this disease including Rituximab, mycophenolate mofetil, and adrenocorticotropic hormone, with an emphasis on results of the most recent clinical trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.